Alaunos Therapeutics Acquires Velaris in Reverse Merger, Raises $350 Million

What happened

Alaunos Therapeutics, Inc., a Nasdaq-listed drug developer with almost no revenue, acquired Velaris Therapeutics, Inc., a private Delaware corporation, on October 13, 2026, according to a Form 8-K filed with the Securities and Exchange Commission that day.

Under the deal, a subsidiary of Alaunos merged into Velaris, and Velaris became a wholly owned subsidiary of Alaunos. Alaunos paid the Velaris stockholders in stock: 105,286 shares of a new Series B Non-Voting Convertible Preferred Stock and 33,054 shares of a new Series C Non-Voting Convertible Preferred Stock. Each preferred share converts into 1,000 shares of Alaunos common stock, subject to conditions described in the filing. Outstanding Velaris stock options were assumed by Alaunos and converted into options for Alaunos common stock.

At the same time, Alaunos signed a securities purchase agreement to sell 687,789 shares of common stock at $1.4357 per share and 243,063 shares of Series C Preferred Stock at $1,435.70 per share, for total proceeds of about $350 million. The filing calls this private placement the Financing and says it is expected to close on October 14, 2026. Alaunos says it intends to use the net proceeds to fund research and development of Velaris's programs and for working capital and general corporate purposes.

Market reaction

Alaunos common stock closed at $3.27 on the event date, up 211.43% from the previous close of $1.05, according to the price data. Volume was 200,062,063 shares against an average volume of 907,278 shares — roughly 220 times the typical daily turnover.

The filing does not state why the shares moved. The price and volume data show the size of the move; the documents do not attribute a cause.

What this means

An 8-K is a current report. Public companies file it with the SEC to disclose material events — things a reasonable investor would want to know — between quarterly and annual reports. This particular 8-K lists items 1.01 (a material agreement), 2.01 (completion of an acquisition or disposition), 3.02 (an unregistered sale of equity), 5.02 (a director or officer change), 5.03 (amendment to charter or bylaws), 7.01 (Regulation FD disclosure) and 9.01 (financial statements and exhibits).

The structure here is what market participants call a reverse merger. Alaunos is the public, listed shell that survives as the legal acquirer, but the private company's shareholders receive new preferred stock that converts into a large block of Alaunos common stock. Alaunos shareholders did not vote on the merger; the filing says stockholder approval was not required. Instead, Alaunos has agreed to hold a stockholders' meeting later to vote on converting the preferred stock into common stock, increasing authorized common shares, changing the company's name to Velaris Therapeutics, Inc., redomesticating the company, effecting a reverse stock split, and approving a new equity incentive plan.

Preferred stock is an ownership stake that ranks ahead of common stock for dividends and in a liquidation, and often carries special voting or conversion rights. The Series B and Series C shares here are non-voting as preferred stock, but each converts into 1,000 common shares. The conversion requires stockholder approval under Nasdaq listing rules because it would result in the issuance of a large number of new common shares; the filing says the company has agreed to seek that approval. Until conversion, the new investors hold preferred stock, not the common shares that trade on Nasdaq under the ticker TCRT.

The Financing is a PIPE — a private investment in public equity. Instead of registering shares with the SEC and selling them in a public offering, the company sells unregistered shares directly to institutional investors under an exemption. The filing says the sale is exempt under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D, which cover transactions by an issuer not involving a public offering. In exchange, the company signs a registration rights agreement requiring it to file a resale registration statement within 30 days of the financing closing, so the investors can eventually sell those shares publicly.

A lock-up agreement restricts insiders from selling shares for a set period — here 180 days — to prevent a flood of selling right after the deal. The filing says the lock-up will be extended if the resale registration statement has not been declared effective by the SEC before that 180-day period ends.

Several other agreements shape control of the company. Stockholder support agreements commit certain Alaunos officers and directors to vote their shares for the proposals at the upcoming meeting. A share repurchase and voting agreement with holders of Alaunos's existing Series A-1 and A-2 preferred stock — including directors Robert W. Postma and Jaime W. Vieser — provides that those holders will convert to common stock before the meeting record date, vote for the proposals, and, after approval of the conversion proposal, have their shares repurchased by the company for cash. The filing says the Merger Agreement also provides that three Alaunos directors will resign upon stockholder approval of the conversion proposal and be replaced by designees of the lead investor, so that the director designated by Velaris and the lead investor's designees will hold four of five board seats. The lead investor also gets consent rights over the development plan and budget until the earlier of conversion, twelve months after closing, or its own agreement.

The filing describes the intended stages: the merger has closed; the financing is expected to close the next day; a resale registration statement is due within 30 days; the proxy statement and stockholder meeting follow. The filing does not state when the meeting will be held or what the reverse-split ratio will be, saying only that the ratio will be determined by the board with the lead investor's consent.

The company

Alaunos Therapeutics is incorporated in Delaware and listed on the Nasdaq Stock Market under the ticker TCRT. Its most recent annual revenue was $5,000 for the period ending December 31, 2025. The filing does not describe Velaris's programs in detail; it refers to "Velaris's programs" and says the financing proceeds will fund their research and development.